Abstract
Amniotic fluid embolism (AFE) is a rare clinical syndrome that occurs intrapartum or immediately postpartum. The exact cause of this syndrome is not known although it is widely suspected that there may be an immune etiology causing an anaphylactoid-like reaction with complement activation. The syndrome occurs with greater frequency in parturients who are older and multiparous, have twin pregnancies, and experience difficult labors. It is also seen more frequently in preeclamptic patients and in women who have Cesarean sections. The classic presentation of this syndrome is cardiopulmonary collapse usually preceded by respiratory failure, cardiogenic shock, disseminated intravascular coagulation (DIC), and neurologic changes including seizures and coma. Severe and refractory hypoxemia results from ventilation/perfusion mismatching as well as from cardiogenic pulmonary edema associated with acute left heart failure. The diagnosis of this syndrome is difficult and AFE remains a diagnosis of exclusion since there are no laboratory or radiographic tests which confirm the diagnosis. The constellation of signs and symptoms in a pregnant woman who experiences the typical symptomology and a high degree of suspicion usually are sufficient to make the diagnosis of AFE.
The management of amniotic fluid embolism syndrome is supportive care. Correcting hypoxemia and hypotension is paramount in preventing further sequelae to the mother and the fetus. If AFE presents intrapartum, the fetus should be delivered immediately to support maternal hemodynamics. Specific therapies such as diuresis and inotropic support should be implemented if there is evidence of left heart failure and congestion. Intra-aortic balloon pump counterpulsation and extracorporeal membrane oxygenation have also been utilized in some patients. Refractory hypotension is managed with vasopressor support. Mechanical ventilation is usually required for severe respiratory failure regardless of the exact cause of the respiratory compromise. DIC is treated with appropriate blood products and recombinant human factor VIIa based on laboratory testing. Most recently, there has been some interest in the use of fresh frozen plasma as a source of C1 esterase since low levels of C1 esterase inhibitor have been detected in survivors of AFE.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Baldisseri MR. Amniotic fluid embolism syndrome. www.uptodate.com. Accessed 19 Jan 15.
Moore J, Baldisseri MR. Amniotic fluid embolism. Crit Care Med. 2005;33(10):S279–85.
Conde-Agudelo A and Romero R. Amniotic fluid embolism: an evidence-based review. AJOG. 2009;201:445.e1–13.
Fitzpatrick K, Tuffnell D, Kurinczuk J, Knight M. Incidence, risk factors, management and outcomes of amniotic-fluid embolism: a population based cohort and nested case control study. BJOG. 2015; doi:10.1111/1471-0528.13300.
Kanayama N, Tamura N. Amniotic fluid embolism: pathophysiology and new strategies for management. J Obstet Gynaecol Res. 2014;40(6):1507–17.
Abenhaim H, Azoulay L, Kramer M and Leduc L. Incidence and risk factors of amniotic fluid embolisms: a population-based study on 3 million births in the United States. AJOG. 2008;199:49.e1–49.e8.
Stein PD, Matta F, Yaekoub AY. Incidence of amniotic fluid embolism: relation to cesarean section and to age. J Womens Health. 2009;18(3):327–9.
Knight M, Tuffnell D, Brocklehurst P, Spark P, Kurinczuk JJ. Incidence and risk factors for amniotic-fluid embolism. Obstet Gynecol. 2010;115:910–7.
McDonnell NJ, Percival V, and Paech MJ. Amniotic fluid embolism: a leading cause of maternal death yet still a medical conundrum. Int J Obstet Anesth. 2013;22:329–36.
Morgan M. Amniotic fluid embolism. Anesthesia. 1979;30:20–6.
Kramer MS, Rouleau J, Baskett TF, Joseph KS. Amniotic fluid embolism and medication induction of labour; a restrospective, population-based cohort study. Lancet. 2006;368:1444–8.
Stolk KH, Zwart JJ, Van Roosmalen J. Severe maternal morbidity and mortality from amniotic fluid embolism in the Netherlands. Acta Obstet Gynecol Scand. 2012;91(8):991–5.
Courtney LD. Amniotic fluid embolism. Obstet Gynecol Surv. 1974;29:169–77.
Clark SL. New concepts of amniotic fluid embolism: a review. Obstet Gynecol Surv. 1990;45:360–8.
Gist RS, Stafford IP, Leibowitz AB, Beilin Y. Amniotic fluid embolism. Anesth Analg. 2009;108:1599–602.
Benson MD. A hypothesis regarding complement activation and amniotic fluid embolism. Med Hypotheses. 2007;68:1019–25.
Benson MD. Current concepts of immunology and diagnosis in amniotic fluid embolism. Clin Dev Immunol. 2012;2012:946576.
Meyer JR. Embolia pulmonary amnio caseosa. Bras Med. 1926;2:301–3.
Steiner PE, Lushbaugh C. Maternal pulmonary embolism by amniotic fluid as a cause of obstetric shock and unexpected deaths in obstetrics. JAMA. 1941;117:1245–54. 1340–5.
Lee W, Ginsburg KA, Cotton DB, Kaufman RH. Squamous and trophoblastc cells in the maternal pulmonary circulation identified by invasive hemodynamic monitoring during the peripartum period. Am J Obstet Gynecol. 1986;155:999–1001.
Benson MD, Kobayashi H, Silver RK, Oi H, Greenberger PA, Terao T. Immunologic studies in presumed amniotic fluid embolism. Obstet Gynecol. 2001;97:510–4.
Legrand M, Rossignol M, Dreux S, Luton D, Ventre C, Barranger E, Laribi S, Payen D, Muller F. Diagnostic accuracy of insulin-like growth factor binding protein-1 for amniotic fluid embolism. Crit Care Med. 2012;40(7):2059–63.
McDonnell NJ, Chan BO, Frengley RW. Rapid reversal of critical haemodynamic cmpromis with nitric oxide in a parturient with amniotic fluid embolism. Int J Obstet Anesth. 2007;16:269–73.
Nagarsheth NP, Pinney S, Bassily-Marcus A, Anyanwu A, Friedman L, Beilin Y. Successful placement of a right ventricular assist device for treatment of a presumed amniotic fluid embolism. Anesth Analg. 2008;107(3):962–4.
Kumar S, Wong G, Maysky M, Shulman M, Olenchock S, Falzon-Kirby M, Oo TH. Amniotic fluid embolism complicated by paradoxical embolism and disseminated intravascular coagulation. Am J Crit Care. 2010;19(4):379–82.
Hsieh YY, Chang CC, Li PC, Tsai HD, Tsai CH. Successful application of extracorporeal membrane oxygenation and intra-aortic balloon counterpulsation as lifesaving therapy for a patient with amniotic fluid embolism. Am J Obstet Gynecol. 2000;183(2):496–7.
Shen HP, Chang WC, Yeh LS, Ho M. Amniotic fluid embolism treated with emergency extracorporeal membrane oxygenation: a case report. J Reprod Med. 2009;54(11-12):706–8.
Leighton BL, Wall MH. Lockhart EM, Phillips LE, Zatta AJ. Use of recombinant factor VIIa in patients with amniotic fluid embolism: a systematic review of case reports. Anesthesiology. 2011;115:1201–8.
Rogers WK, Wernimont SA, Kumar GC, Bennett E, Chestnut DH. Acute hypotension associated with intraoperative cell salvage using a leukocyte depletion filter during management of obstetric hemorrhage due to amniotic fluid embolism. Anesth Analg. 2013;117(2):449–52.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Cheng, S.H., Baldisseri, M.R. (2017). Management of Amniotic Fluid Embolism. In: Hyzy, R. (eds) Evidence-Based Critical Care. Springer, Cham. https://doi.org/10.1007/978-3-319-43341-7_88
Download citation
DOI: https://doi.org/10.1007/978-3-319-43341-7_88
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-43339-4
Online ISBN: 978-3-319-43341-7
eBook Packages: MedicineMedicine (R0)